Clinical Trial Update: Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lamivudine plus a therapeutic hepatitis B vaccine in Senegalese patients with chronic hepatitis B was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HBV Therapeutic Vaccine (HBV therapeutic vaccine)
• Lamivudine (lamivudine)

Snippet

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis | Conditions: Hepatitis B | Phase 3 | Status: TERMINATED